

**VIA First Class Mail**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service by First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, Va. 22313-1450 on the date shown below.

LUD 5483.7-DIV (10316191)

*Eileen Sheffield* 4/16/04  
Eileen Sheffield

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Applicant

Danila Valmori, et al.

Serial No.

10/758,673

Filed

January 16, 2004

For

ISOLATED NUCLEIC ACID MOLECULES WHICH  
ENCODE PEPTIDES THAT BIND TO HLA MOLECULES  
AND THE USES THEREOF

April 16, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA. 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

SIRS:

In accordance with 37 C.F.R. §§1.97 and 1.98, applicants provide the following list of documents and the corresponding PTO Form 1449.

**U.S. Patents**

1. U.S. Patent No. 5,487,974 to Boon-Falleur et al. (January 1996);
2. U.S. Patent No. 5,554,506 to van der Bruggen et al. (September 1996); and
3. U.S. Patent No. 5,554,724 to Melief et al. (September 1996).

**PCT Applications**

4. PCT Application WO95/29193 to Kawakami et al. (November 1995).

**Journal Articles**

1. Anichini et al., "Cytolytic T Cells Directed To Tumor Antigens Not Expressed On Normal Melanocytes Dominate HLA-A2.1 Restricted Immune Repertoire To Melanoma," J. Immunol., 156:208-217 (1996);
2. Coulie et al., "A New Gene Coding For A Differentiation Antigen Recognized by Autologous Cytolytic T Lymphocytes On HLA-A2 Melanomas," J. Exp. Med., 180:35-42 (1994);
3. Falk et al., "Allele Specific Motifs Revealed By Sequencing of Self Peptides Eluted From MHC Molecules," Nature, 351:290-296 (1991);
4. Hunt et al., "Characterization of Peptides Bound to the Class-1 MHC Molecules HLA-A2.1 By Mass Spectrometry," Science, 255:1261-1263 (1992);
5. Loftus et al., "Identification of Epitope Mimics Recognized by CTL Reactive to the Melanoma/Melanocyte-derived Peptide MART-1 (27-35)," J. Exp. Med., 184:647-657 (1996);
6. Pancor et al., J. Immunology, 149:3580 (1992);
7. Ochoa-Garay et al., Mol. Immunol., 34:273 (1997);
8. Rammensee et al., "MHC Ligands and Peptide Motifs: First Listing," Immunogenics, 41:178-228 (1995);
9. Romero et al., "Cytolytic T Lymphocyte Recognition of the Immunodominant HLA-A\*0201-Restricted Melan-A/MART-1 Antigenic Peptide in Melanoma", J. Immunol., 159:2366-2374 (1997);
10. Ruppert et al., "Prominent Role of Secondary Anchor Residues In Peptide Binding to HLA-A2.1 Molecules," Cell, 74:929-937 (1993);
11. Slinguff et al., "Recognition of Human Melanoma Cells By HLA-A2.1 Restricted Cytolytic T Lymphocytes Is Mediated By At Least Six Shared Peptide Epitopes," J. Immunol., 150(7):2955-2963 (1993);
12. Valmori et al., "Enhanced Generation of Specific Tumor-Reactive CTL In Vitro by Selected Melan-A/MART-1 Immunodominant Peptide Analogues", J. Immunol., 160:1750-1758 (1998);

13. van der Bruggen et al., "A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3," Eur. J. Immunol., 24:3038-3043 (1994);
14. Wölfel et al., "Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes," Eur. J. Immunol., 24:759-764 (1994); and
15. Wölfel et al., "Analysis of Antigens Recognized on Human Melanoma Cells By A2 Restricted Cytolytic T Lymphocytes," Int. J. Cancer, 55:237-244 (1993).


**REMARKS**

The undersigned hereby certifies that this statement is being filed before the mailing date of a First Office Action.

Applicants believe no fee is required for filing these papers. However, the Commissioner is hereby authorized to deduct any fee due, or credit any overpayment to Deposit Account No. 50-0624.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.

A handwritten signature in black ink, appearing to read 'Norman D. Hanson', is written over a horizontal line.

Norman D. Hanson, Esq.  
Registration No. 30,946

666 Fifth Avenue  
New York, NY 10103  
(212) 318-3000


PREV. 77921449 (Modified)

Patent and Trademark Office

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use several sheets if necessary)

(37 CFR 1.98(b))



ATTY. DOCKET NO.

SERIAL NO.

LUD-5483.7-US-Div.

10/758,673

APPLICANT

Danila VALMORI et al.

FILING DATE

January 16, 2004

GROUP

**U.S. PATENT DOCUMENTS**

*Examiner Initial	Patent Number	Issue Date	Patentee	Class	Subclasses	Filing Date (if appropriate)
	5,487,974	01/96	Boon-Falleur et al.			
	5,554,506	09/96	van der Bruggen et al.			
	5,554,724	09/96	Melief et al.			

**FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION**

	Document Number	Date	Country	Class	Subclasses	Translation	
						Yes	No
	95/29193	11/95	WO				

**OTHER DOCUMENTS**

(INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	Anichini et al., <i>J. Immunol.</i> , 156:208-217 (1996)
	Coulie et al., <i>J. Exp. Med.</i> , 180:35-42 (1994)
	Falk et al., <i>Nature</i> , 351:290-296 (1991)
	Hunt et al., <i>Science</i> , 255:1261-1263 (1992)
	Loftus et al., <i>J. Exp. Med.</i> , 184:647-657 (1996)
	Pancor et al., <i>J. Immunology</i> , 149:3580 (1992)
	Ochoa-Garay et al., <i>Mol. Immunol.</i> , 34:273 (1997)
	Rammensee et al., <i>Immunogenics</i> , 41:178-228 (1995)
	Romero et al., <i>J. Immunol.</i> , 159:2366-2374 (1997)
	Ruppert et al., <i>Cell</i> , 74:929-937 (1993)
	Slinguff et al., <i>J. Immunol.</i> , 150(7):2955-2963 (1993)
	Valmori et al., <i>J. Immunol.</i> , 160:1750-1758 (1998)
	van der Bruggen et al., <i>Eur. J. Immunol.</i> , 24:3038-3043 (1994)
	Wölfel et al., <i>Eur. J. Immunol.</i> , 24:759-764 (1994)
	Wölfel et al., <i>Int. J. Cancer</i> , 55:237-244 (1993)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP \* 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.